Celldex Therapeutics, Inc. (NASDAQ:CLDX) To Make Presentation At Cowen and Company 35th Annual Health Care Conference


In order to talk about its recent corporate performance, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has decided to make a presentation at Cowen and Company 35th Annual Health Care Conference. The presentation will cover a corporate overview, various milestones that it achieved in 2014 and the financial performance of the company.

Insights On The Matter:       

The conference is scheduled to take place at the Boston Marriott Copley Place Hotel in Boston on Wednesday, March 4, 2015. Management of the company is very optimistic about this event. It’s going to be an important event for the company; therefore, it has requested all the stakeholders to take out some time and be present during the presentation.

Those who are not able to attend the presentation can access the live webcast of it, which will be available on the Events & Presentations page. Interested people can log in to the official website of the company and click on “Investors & Media” section to get access of this webcast. Those who cannot attend the live presentation due to some emergency, have another chance to watch it on March 11, 2015. The company has decided to play a repeat telecast on that day to ensure that maximum people can access the presentation.

There are various diseases in this world, which have no adequate treatments. Hundreds of thousands of people die due to lack of resources and awareness. CLDX looks forward to developing targeted therapeutics to address such life threatening diseases. In order to develop efficient solutions, Celldex Therapeutics, Inc. (NASDAQ:CLDX) uses a portfolio of various immunomodulators and antibodies. They are used in different combinations, ratios and quantities to create disease-specific and novel therapies that enhance, induce or suppress the immune system of the body. During the presentation, CLDX will cover the milestones that it achieved in the previous year and the therapies that are in the pipeline.


Please enter your comment!
Please enter your name here